Related Experiment Videos
Adjuvant postoperative combined-modality therapy for rectal cancer
1Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Oncology (Williston Park, N.Y.)
|August 12, 1999
Summary
Adjuvant chemotherapy improves outcomes for resectable rectal cancer. Combining systemic chemotherapy with pelvic radiation therapy enhances local control and survival rates in rectal cancer patients.
Area of Science:
- Oncology
- Surgical Oncology
- Gastrointestinal Oncology
Background:
- Adjuvant chemotherapy plays a crucial role in managing resectable rectal cancer.
- Pelvic radiation therapy improves local control but systemic therapy is needed for better survival.
- Current treatment strategies aim to optimize both local control and overall survival.
Purpose of the Study:
- To review the current use of adjuvant chemotherapy in resectable rectal cancer.
- To examine the postoperative adjuvant setting for rectal cancer treatment.
- To discuss data from recent trials and innovative phase I/II programs.
Main Methods:
- Review of randomized trials in adjuvant chemotherapy for rectal cancer.
- Analysis of data from completed and ongoing clinical trials.
- Discussion of novel phase I/II program designs.
Main Results:
- Adjuvant chemotherapy, alongside pelvic radiation, is essential for improving outcomes.
- Systemic chemotherapy is necessary to enhance local control and overall survival.
- Ongoing research and trials are exploring optimized treatment regimens.
Conclusions:
- Adjuvant chemotherapy is a vital component of multimodal therapy for resectable rectal cancer.
- Further research and clinical trials are critical for refining treatment strategies.
- Optimizing adjuvant chemotherapy regimens can lead to improved patient survival and quality of life.